Page last updated: 2024-11-02
oxybutynin and Dyskinesia, Medication-Induced
oxybutynin has been researched along with Dyskinesia, Medication-Induced in 1 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| " Primary outcomes included adverse events (AEs) and extent of rotigotine exposure." | 2.78 | The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease. ( Boroojerdi, B; Giladi, N; Surmann, E, 2013) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Giladi, N | 1 |
| Boroojerdi, B | 1 |
| Surmann, E | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| An Open-Label Extension to the Double-Blind SP513 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease[NCT00599196] | Phase 3 | 381 participants (Actual) | Interventional | 2002-08-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Number of Subjects Who Withdrew From the Trial Due to an Adverse Event
Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment. (NCT00599196)
Timeframe: six years
| Intervention | Subjects (Number) |
|---|
| Rotigotine | 93 |
Number of Subjects With at Least One Adverse Event During This Open-label Extension Study
Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment. (NCT00599196)
Timeframe: six years
| Intervention | Subjects (Number) |
|---|
| Rotigotine | 369 |
Mean Epworth Sleepiness Scale Score During the Open-label Extension
The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. The total ESS score is the sum of 8 item-scores and can range between 0 and 24. The higher the score, the higher the person's level of daytime sleepiness. (NCT00599196)
Timeframe: Visit 10 (end of year 1), Visit 14 (end of year 2), Visit 18 (end of year 3), Visit 22 (end of year 4), Visit 26 (end of year 5), Visit 30 (end of year 6), End of Treatment (last study visit or early withdrawal visit)
| Intervention | Score on a scale (Mean) |
|---|
| Visit 10 (end of year 1) (n=375) | Visit 14 (end of year 2) (n=375) | Visit 18 (end of year 3) (n=375) | Visit 22 (end of year 4) (n=375) | Visit 26 (end of year 5) (n=375) | Visit 30 (end of year 6) (n=375) | End of Treatment (n=377) |
|---|
| Rotigotine | 5.8 | 6.2 | 6.7 | 6.7 | 6.7 | 6.8 | 6.8 |
Trials
1 trial available for oxybutynin and Dyskinesia, Medication-Induced